FDA OKs Long-Acting Atypical Antipsychotic for Schizophrenia
Aristada (aripiprazole lauroxil) is injected every four-to-six weeks
TUESDAY, Oct. 6, 2015 (HealthDay News) -- Aristada (aripiprazole lauroxil) extended-release injection has been approved by the U.S. Food and Drug Administration to treat schizophrenia, the agency said Tuesday in a news release.
Aristada's effectiveness was demonstrated in a 12-week clinical study involving 622 patients. In participants with acute schizophrenia who had been stabilized with oral aripiprazole, Aristada was found to maintain the treatment effect compared to a placebo. The most common side effect reported was akathisia.
As with other atypical antipsychotics, Aristada includes a boxed warning against off-label use that may increase the risk of death among older people with dementia-related psychosis.
"Long-acting medications to treat schizophrenia can improve the lives of patients," Mitchell Mathis, M.D., director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, said in a statement. "Having a variety of treatment options and dosage forms available for patients with mental illness is important so that a treatment plan can be tailored to meet the patient's needs."
Aristada is manufactured by Alkermes, Inc., based in Waltham, Mass.